The effects of IL-2/mAb complexes on Tregs and migration to GCs are better understood through an experiment using chronic graft-versus-host disease (cGVHD) in which administration of IL-2/mAb complexes increased splenic Tregs and TFR while ameliorating cGVHD without increasing TFH [94]. Here, IL2 is linked to chronic graft versus host disease.